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Millennium Institute and Westmead Hospital, University of Sydney, AustraliaSummary IntroductionNon-alcoholic fatty liver disease (NAFLD) is a frequent accompa-
niment of obesity and insulin resistance. With the prevalence
approaching 85% in obese populations, new therapeutic
approaches to manage NAFLD are warranted.
A systematic search of the literature was conducted for studies
pertaining to the effect of omega-3 polyunsaturated fatty acid
(PUFA) supplementation on NAFLD in humans. Primary outcome
measures were liver fat and liver function tests: alanine amino-
transferase (ALT) and aspartate aminotransferase [1]. Data were
pooled and meta-analyses conducted using a random effects
model. Nine eligible studies, involving 355 individuals given
either omega-3 PUFA or control treatment were included. Beneﬁ-
cial changes in liver fat favoured PUFA treatment (effect
size = 0.97, 95% CI: 0.58 to 1.35, p <0.001). A beneﬁt of PUFA
vs. control was also observed for AST (effect size = 0.97, 95% CI:
0.13 to 1.82, p = 0.02). There was a trend towards favouring
PUFA treatment on ALT but this was not signiﬁcant (effect
size = 0.56, 95% CI: 1.16 to 0.03, p = 0.06). Sub-analyses of only
randomised control trials (RCTs) showed a signiﬁcant beneﬁt for
PUFA vs. control on liver fat (effect size = 0.96, 95% CI: 0.43 to
1.48, p <0.001), but not for ALT (p = 0.74) or AST (p = 0.28).
There was signiﬁcant heterogeneity between studies. The pooled
data suggest that omega-3 PUFA supplementation may decrease
liver fat, however, the optimal dose is currently not known. Well
designed RCTs which quantify the magnitude of effect of omega-3
PUFA supplementation on liver fat are needed.
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by Elsevier B.V. All rights reserved.Journal of Hepatology 20
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proliferator activated receptor a.Non-alcoholic fatty liver disease (NAFLD) is characterised by
increased hepatic fat accumulation in individuals not consuming
excessive alcohol and represents a spectrum of disease ranging
from ‘simple’ steatosis to non-alcoholic steatohepatitis [2], which
is only distinguishable by histological examination [3,4].
Non-alcoholic steatohepatitis (NASH), the inﬂammatory compo-
nent, predisposes to hepatic ﬁbrosis, cirrhosis, and subsequent
end-stage liver disease and hepatocellular carcinoma [5–7].
NAFLD is independently associated with coronary heart disease
[8], insulin resistance [9,10], and type II diabetes [10,11]. In
Western populations, the prevalence of NAFLD may exceed 30%
[12], and can be as high as 88% in the obese [13]. Risk factors
for the development of NAFLD include central obesity, type II
diabetes, dyslipidemia, and hypertension [10,11,13–15]. Given
the increasing prevalence and incidence of these conditions
[16–21], the global burden of NAFLD is expected to increase.
Currently, the primary treatment for NAFLD is weight loss by
lifestyle therapy involving diet and exercise. Weight loss has been
shown to improve liver enzymes [22–24], decrease plasma
triglycerides [23,25] and improve liver fatness, as measured by
magnetic resonance spectroscopy (MRS), ultrasonography or
direct histological evaluation [25–27]. Major reductions in weight
and consequent improvements in liver pathology can also be
achieved by bariatric surgery [23,25], but this is not feasible for
the large number of patients presenting with this disease
[20,28–31]. Similarly, pharmacotherapy including insulin
sensitisers, hypolipidemics and vitamin E [2,32] have been tri-
alled in small cohorts and their effectiveness is limited by poor
compliance [33,34], associated weight gain [32], and side-effects
[35]. Current evidence from available randomised control trials
suggests that only thiazolidinediones actually reduce liver fat
[2,32,35].
Although studies investigating the dietary patterns of patients
with NAFLD vs. controls have reported conﬂicting results with
respect to the importance of macronutrient composition
[36–41], several studies have implicated dietary alteration
beyond gross macronutrient change as causal in the development
of NAFLD. When compared with controls, individuals with NAFLD
have been shown to have lower ﬁsh [41] and polyunsaturated fat
intake [38] and a higher n6/n3 consumption [36]. Accordingly,12 vol. 56 j 944–951
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analysis of the composition of hepatic long chain fatty acids has
shown a decrease in the relative levels of n3 PUFA (polyunsat-
urated fatty acids) in patients with NAFLD compared with con-
trols, and an increase in the hepatic n6/n3 PUFA ratio
[1,42,43]. These ﬁndings have been conﬁrmed in animal studies
[44].
Given the well-recognised problems of adherence to lifestyle
interventions, achieving sustainable weight loss, and side-effects
with pharmacological agents, dietary ﬁsh oil supplementation
represents a simple and practical alternative therapy. Fish oil pro-
vides a convenient source of essential n3 PUFA with few side
effects [45–48] and may directly reduce hepatic lipogenesis and
steatosis [1,49]. A recent systematic review of available random-
ised controlled trials which included subanalysis of the efﬁcacy of
n3 PUFA supplementation for reducing alanine aminotransfer-
ase (ALT) levels failed to provide a deﬁnitive conclusion regarding
its efﬁcacy in reducing liver fat in humans [32]. The authors cited
heterogeneity in population and study design and a lack of post-
treatment histology as barriers to meta-analysis of the effect of
PUFA on liver fatness [32]. However, there is a considerable body
of additional evidence, including more recent RCT (randomised
controlled trial) data, which suggests that ﬁsh oil supplementa-
tion is an efﬁcacious therapy for achieving hepatic beneﬁts.
Therefore, the aim of this study was to conduct a systematic
review and meta-analysis of all human trials assessing the efﬁ-
cacy of dietary n3 PUFA supplementation on modifying hepatic
fat content and serum aminotransferases in adults.Methods
A systematic literature search was conducted by one researcher (HP) to identify
and appraise studies of omega-3 fatty acids or ﬁsh oil supplementation in NAFLD
or NASH. Databases searched from inception to November 2010 were: Medline
(Ovid), Cinahl (EBSCO Host), AMED (Ovid), Web of Science (ISI Web of Knowl-
edge), Scopus, CAM, Embase, ProQuest 5000, Science Direct and PubMed. The ref-
erence lists of review articles were hand-searched for additional relevant studies.
Search terms were: ‘ﬁsh oil’, ‘EPA’ (eicosapentaenoic acid), ‘eicosapentaenoic
acid’, ‘eicosapentanoic acid’, ‘DHA’ (docosahexaenoic acid), ‘docosahexaenoic
acid’, ‘docosahexanoic acid’, ‘omega-3’, ‘omega-3’, ‘n3’, and ‘NAFLD’, ‘fatty liver’
‘hepatic steatosis’, ‘hepatic’, ‘liver’, ‘steatohepatitis’, ‘NASH’, ‘aminotransferase’,
‘ALT’, and ‘AST’.
Inclusion and exclusion criteria
Inclusion and exclusion criteria were determined a priori by two researchers (HP
and NJ). Two researchers (HP and CB) also determined studies eligible for review.
Included studies employed trials involving oral administration of omega-3 fatty
acid supplementation in male and/or female adult (P18 years) humans, including
both NAFLD and NASH cohorts where this was speciﬁed. Studies were excluded if
they addressed alcoholic, drug-induced, total parenteral nutrition-induced, viral
or genetic causes of liver injury. Studies were not limited to the English language,
nor limited by design. Studies were excluded based on ﬁle type: book sections,
ﬁlm/broadcast, opinion articles, observational studies, abstracts without ade-
quate data or reviews.
Data extraction
Outcome measures used in this review were: liver fatness quantiﬁed by needle
biopsy and histological assessment, proton magnetic resonance spectroscopy
(1H MRS), or inferred by ultrasonography; and plasma alanine aminotransferase
(ALT) and aspartate aminotransferase [1] levels. Data on participants, interven-
tions, adverse events, dietary assessment, statistical analyses, pre-test standardi-
sation, and diet control were extracted. Authors were contacted if further details
were needed. Where required, means and standard deviations were calculated
using appropriate equations [50].Journal of Hepatology 201Analyses and meta-analyses
The between-trial standardised mean difference, or effect size (ES), and 95% con-
ﬁdence intervals (CI) were calculated. The ES was used to standardise changes of
liver fat and aminotransferases. Pooled estimates of the effect of PUFA supple-
mentation on liver fat and aminotransferases, using ES, were obtained using a
ﬁxed-effects model. We presumed a correlation of 0.5 between outcomes mea-
sured within each comparison group. Between-study variability was examined
using the I2 measure of inconsistency. This statistic, expressed as a percentage
between 0 and 100, provides a measure of how much of the variability between
studies is due to heterogeneity rather than chance. Where signiﬁcant heterogene-
ity was observed, we analysed data by random effects model.
We performed three analyses to compare the effect of (i) PUFA vs. control on
liver fat change, (ii) PUFA vs. control on ALT change, and (iii) PUFA vs. control on
AST change. Sub-analyses were also performed a priori for studies which used RCT
design. All analyses were conducted using Comprehensive Meta-analysis Version
2, Biostat, Englewood NJ (2005).
Study quality assessment
Study quality was assessed by two researchers/reviewers (HP and CB) using a
modiﬁed Downs and Black checklist [51]. The population for checklist items 11
and 12 was deﬁned as any adult with NAFLD or NASH. The ‘usual treatment’
for NAFLD (item 13) was deﬁned as the instruction for the patient to lose weight
by changing diet, increasing exercise or both. Potential confounders (item 5) were
age, gender, BMI, baseline biochemistry, change in diet/exercise, medications and
alcohol intake. For item 27, power was calculated (G power reference) for each
study based on change in liver fatness where p <0.05 and adequate power
P0.8. A score of 1 was given for adequate power, and 0 for inadequate power
or if power could not be calculated. Where reviewers disagreed, speciﬁc criteria
were discussed with a third reviewer (NJ) until consensus was reached. If an item
was unable to be determined a ‘no’ was given.Results
A total of 23,231 non-duplicated entries were identiﬁed by the
systematic search and titles and abstracts were reviewed. Full
text was obtained for articles where title and abstract alone were
insufﬁcient to determine eligibility for inclusion. Ten studies
were deemed relevant from the search; one was excluded after
contacting the authors as only the abstract was available review
[52]. The remaining nine studies are summarised in Table 1.
Four of the included studies were RCTs [48,53–55]. The
remaining ﬁve studies employed: randomised placebo controlled
cross-over design (n = 1; [56]); quasi experimental cross-over
design (n = 1; [57]); quasi experimental design, in which all par-
ticipants underwent omega-3 treatment and those who refused
treatment were considered as the control group (n = 1; [45]);
and uncontrolled design, in which all participants underwent
omega-3 treatment (n = 2; [46,47]). There were no reports of
adverse effects of omega-3 PUFA supplementation in the studies
reviewed (Fig. 1).
Data was analysed for 355 individuals who participated in the
nine studies; 200 were male (56.3%). The median duration of
treatment with omega-3 fatty acids was 6 months (range:
8 weeks to 12 months). The median dose of PUFAs was 4 g/day
(range: 0.8–13.7 g/day). Six studies speciﬁed the dosage of EPA
and DHA (range: 0.375–4.626 g of EPA per day; 0.24–2.24 g of
DHA per day). One study used highly puriﬁed EPA only [47].
Three studies gave dietary recommendations to all participants
[48,53,54] and three studies advised on weight reduction by calo-
ric restriction for participants who were overweight or obese
[46,48,54]. These concurrent interventions were given to both
the treatment and control groups. In all conditions, subjects were
advised to maintain their usual physical activity habits.2 vol. 56 j 944–951 945
Table 1. Characteristics of included studies.
Authors, year
[Ref.]
N 
(total)
Population (method of diagnosis); 
Gender; 
Mean BMI category 
Dose
n-3/day
Duration Control Other instructions
Capanni et al., (2006)
[45]
56 NAFLD (ultrasound); 
M/F; 
Overweight
1 g 12 mo No treatment -
Chen et al., (2008)
[55]
46 NAFLD (elevated LFTs and TGs); 
M/F; 
5 g 24 wk Placebo -
Cussons et al., (2009)
[56]
25 Pre-menopausal women with 
PCOS; 
Obese
4 g 8 wk Placebo Maintain usual dietary and 
activity habits
Hatzitolios et al., 
(2004)
[46]
73 Mixed dyslipidemia 
(>1 of: fasting serum cholesterol 
>220 mg/dl; serum TG >200 mg/dl; 
HDL <45 mg/dl); 
M/F; 
Overweight
13.7 g 24 wk Alternative 
medication 
(atorvastatin, 
orlistat)
BMI >25: advised weight 
reduction 
et al., (2010)
[53]
11 Persistently (>6 mo) elevated serum 
ALT + ultrasonographic features 
indicative of fatty liver; M/F; 
Overweight
0.83 g 12 mo Placebo Dietary recommendations 
Spadaro et al., (2008)
[54]
36 NAFLD (elevated ALT + ultrasound); 
M/F; 
Obese
2 g 6 mo No placebo Calorie restricted AHA 
recommended diet
Tanaka et al., (2008)
[47]
23 Biopsy-proven NASH; 
M/F; 
Overweight
2.7 g 12 mo - Maintain usual medications, 
dietary and activity habits
Vega et al., (2008)
[57]
16 Subset of DHS cohort: elevated 
HTGC (MRS), + average ALT within 
reference range; 
M/F; 
Obese
9 g 8 wk Placebo -
Zhu et al., (2008)
[48]
134 NAFLD associated with mixed 
dyslipidaemia; 
M/F; 
Overweight
2 g 24 wk Placebo AHA recommended diet; 
overweight and obese: 
advised caloric restriction 
(25-30 kcal/kg BW/day) for 
weight loss
Not specified
Sofi
(not specified)
ReviewMeasurement methods used to quantify change in liver fat-
ness included ultrasound (seven studies), magnetic resonance
spectroscopy (two studies), and liver biopsy (two studies; with
eight patients in total having repeat biopsies).
For the purposes of data pooling and analysis, the ‘high dose’
group was selected as the ‘treatment’ group for analysis in the
study by Chen et al. [55]; and it was deemed that there was no
appropriate ‘control’ group in the study by Hatzitolios et al.
[46] as the two other groups of participants each received lipid-
lowering pharmacological agents, not placebo or no treatment.
Effect of ﬁsh oil on liver fat and liver tests
The effect of ﬁsh oil/omega-3 therapy on liver fatness and func-
tion is summarised in Table 1 and Figs. 2–4. Seven studies pro-
vided sufﬁcient data to enable calculation of mean differences,
effect size and 95% conﬁdence intervals (95% CI) for liver fat,
seven studies for ALT, and six studies for AST (Figs. 2–4). For liver
fat, six of the seven studies showed an ES favouring PUFA ther-
apy, ranging from 0.48 to 1.72 (p <0.001). Six of these studies
showed a statistically signiﬁcant effect for PUFA supplementation946 Journal of Hepatology 201on liver fat. Two of the seven studies showed an ES favouring
PUFA therapy on ALT, ranging from 0.90 to 2.35, both of which
were statistically signiﬁcant. One study showed an ES favouring
the control condition on ALT which was signiﬁcant [48]. Of the
six studies which measured AST, three studies showed an ES
favouring PUFA therapy, ranging from 0.84 to 2.86, all of
which were statistically signiﬁcant. One study showed an ES
favouring the control condition on AST which was statistically
signiﬁcant.
Quality analysis
The results of quality analysis are detailed in Supplementary
Table 1. External validity, measures of compliance, blinding of
subjects and data collectors, and researchers blinding to ran-
domisation until the completion of the study were poorly exe-
cuted and/or poorly reported. These limitations can be
attributed to the pilot nature of some studies where no randomi-
sation or no control group was formed. Four of the nine studies
achieved adequate power to detect a change in liver fat; two
studies had insufﬁcient data to calculate power for liver fat.2 vol. 56 j 944–951
Articles 
(after removal of duplicates)
n = 23,592
Excluded articles based on file type
(book section, film/broadcast)
n = 2298
Excluded articles:
• irrelevant
• other diseases/conditions
• other nutrients, nutraceuticals
• pharmacotherapy
• animal studies not addressing
omega-3, fatty liver or its 
associated risk factors 
n = 20,998
Articles deemed 
relevant to general topic
n = 296
Articles excluded by abstract
n = 285
Excluded : 
• omega-3 from food, not 
supplementation, n = 1
• abstract only available after
contacting the authors, n = 1
Articles
n = 11
Articles included 
in the analyses
n = 9
Fig. 1. Flowchart showing the process for the inclusion of studies.
Authors, year 
[Ref.]
Effect size p
Hedge’s g 95% CI
Capanni et al., 2006
Sofi et al., 2010
[45]
-0.938 -1.559, -0.316 0.003
[53]
-0.811 -1.948, 0.326 0.162
Spadaro et al., 2008
[54]
-1.709 -2.460, -0.958 0.000
Zhu et al., 2008
[48]
-0.626 -0.971, -0.281 0.000
Cussons et al., 2009
[56]
-1.718 -2.326, -1.109 0.000
Tanaka et al., 2008
[47]
-0.476 -0.894, -0.058 0.026
Chen et al., 2008
[55]
-0.731 -1.441, -0.021 0.043
-0.965 -1.348, -0.582 0.000
-3.00
Fig. 2. Meta-analysis of effect of omega-3 supplementation on liver fat using a rand
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Liver fat
There was a signiﬁcant pooled ES for the efﬁcacy of PUFA therapy
on liver fat (ES = 0.84, 95% CI: 0.64 to 1.05; p <0.001). Signif-
icant heterogeneity among studies was observed (I2 = 66.12%,
p = 0.007). Using a random effect model, there was a signiﬁcant
pooled ES for the efﬁcacy of PUFA therapy on liver fat
(ES = 0.97, 95% CI: 0.58 to 1.35; p <0.001) (Fig. 2). When only
RCT data were analysed, there remained a signiﬁcant pooled ES
for the efﬁcacy of PUFA therapy on liver fat (ES = 0.96, 95% CI:
0.43 to 1.48; p <0.001).
ALT
There was a signiﬁcant pooled ES for the efﬁcacy of PUFA therapy
on ALT (ES = 0.25, 95% CI: 0.06 to 0.44, p = 0.01), however,
signiﬁcant heterogeneity was found to exist between studies:
I2 = 88.32% (p <0.001). With the random effects model, the pooled
ES for ALT showed a trend toward PUFA therapy vs. control on
ALT but this did not reach statistical signiﬁcance (ES = 0.56,
95% CI: 0.03 to 1.16, p = 0.06) (Fig. 3). When only RCT data
were analysed, there was no signiﬁcant pooled ES for the efﬁcacy
of PUFA therapy on ALT (ES = 0.18, 95% CI: 0.81 to 0.58;
p = 0.74).
AST
There was a signiﬁcant pooled ES favouring PUFA therapy vs. con-
trol on AST (ES = 0.38, 95% CI: 0.16 to 0.60, p <0.001). Signif-
icant heterogeneity was found to exist between studies:
I2 = 91.62% (p <0.001). Using random effects model, there was a
signiﬁcant pooled ES favouring PUFA therapy vs. control on AST
(ES = 0.97, 95% CI: 0.13 to 1.82, p = 0.02) (Fig. 4). However,
when only RCT data were analysed, there was no signiﬁcant
pooled ES for the efﬁcacy of PUFA therapy on AST (ES = 0.72,
95% CI: 2.02 to 0.58; p = 0.28).Effect size and 95% CI
3.00-1.50 1.50-0.00
Favors PUFA Favors control
om effects model.
2 vol. 56 j 944–951 947
Authors, year 
[Ref.]
Effect size p Effect size and 95% CI
Hedge’s g 95% CI
Capanni et al., 2006
[45]
-0.458 -1.060, 0.144 0.136
[53]
-0.517 -1.623, 0.590 0.360
Spadaro et al., 2008
[54]
-0.477 -1.125, 0.172 0.150
Zhu et al., 2008
[48]
0.363 0.023, 0.702 0.036
Hatzitolios et al., 2004
[46]
-2.351 -3.137, -1.566 0.000
Cussons et al., 2009
[56]
0.089 -0.291, 0.469 0.646
Tanaka et al., 2008
[47]
-0.896 -1.368, -0.424 0.000
-0.563 -1.158, 0.031 0.063
Sofi et al., 2010
-4.00 4.00-2.00 2.000.00
Favors PUFA Favors control
Fig. 3. Meta-analysis of effect of omega-3 supplementation on ALT using a random effects model.
Authors, year 
[Ref.]
Effect size p Effect size and 95% CI
Hedge’s g 95% CI
Capanni et al., 2006
[45]
-0.607 -1.214, 0.000 0.050
[53]
-2.859 -4.473, -1.245 0.001
Spadaro et al., 2008
[54]
-0.439 -1.086, 0.207 0.183
Zhu et al., 2008
[48]
0.435 0.094, 0.776 0.012
Hatzitolios et al., 2004
[46]
-2.365 -3.154, -1.576 0.000
Tanaka et al., 2008
[47]
-0.840 -1.303, -0.377 0.000
-0.971 -1.815, -0.127 0.024
Sofi et al., 2010
-5.00 5.00-2.50 2.500.00
Favors PUFA Favors control
Fig. 4. Meta-analysis of effect of omega-3 supplementation on AST using a random effects model.
ReviewDiscussion
The present investigation provides the ﬁrst meta-analysis of
studies investigating the effect of omega-3 PUFA on liver fat in
humans. The data show that, despite signiﬁcant heterogeneity
in study design, marine omega-3 fatty acid supplementation in
humans is associated with a positive effect on liver fat. Impor-
tantly, this effect persisted when only RCTs were examined.
Despite a signiﬁcant beneﬁt of PUFA therapy on AST and a ten-
dency toward a beneﬁt on ALT, these effects were not signiﬁcant
after examination of only RCT data.
Our results build on the ﬁndings of a recent review by Musso
et al. [32], which provided a meta-analysis of ALT data from three
RCTs available at that time. The current review pooled data from948 Journal of Hepatology 201a larger number of studies and showed a beneﬁt on liver fatness,
but like Musso et al., found no signiﬁcant beneﬁt on ALT levels.
The current data also suggest that AST is unaffected by PUFA sup-
plementation. However, there was a lack of well-controlled, ran-
domised trials, and consequently a lower overall quality rating
for the available data. Furthermore, it is well acknowledged that
there is high intra-individual variability in liver tests which may
reduce the ability to detect signiﬁcant changes in these parame-
ters with interventions.
Although nine studies were identiﬁed that examined the
effect of dietary omega-3 PUFA supplementation on liver fat,
two studies [46,57] could not be included in liver fat analyses
because of insufﬁcient data. Two and three studies had insufﬁ-
cient data for inclusion in ALT analyses [55,57] and AST analyses2 vol. 56 j 944–951
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[55–57], respectively. There was signiﬁcant statistical heteroge-
neity between studies, and study design varied markedly. Four
studies employed non-randomised designs, duration of interven-
tion ranged from 8 weeks to 12 months (median: 6 months), and
dose of omega-3 PUFA ranged from 0.8 to 13.7 g per day (median:
4 g/day). When considering the effect of duration of intervention
on the study results, the magnitude of change in liver fat and liver
enzymes was not a function of duration of dietary supplementa-
tion with omega-3 PUFA because studies of long duration
(12 months) [45,47,53] yielded similar or even smaller-
magnitude changes to those of short [56] or medium
[46,48,54,55] duration (Figs. 2–4). Although no studies reported
compliance rate, the similar magnitude of effect may be due to
lower average compliance over the longer period of intervention.
Dose of omega-3 PUFA also did not appear to alter the effect of
supplementation: over the same duration of intervention
(6 months), omega-3 PUFA dose of 5 g per day gave a reduction
in steatosis grade ES: 0.73 (95% CI: 0.02 to 1.44) [55], while
2 g omega-3 PUFA per day gave a similar effect size for a reduc-
tion in steatosis grade: 0.63 (0.97 to 0.28) [48]. Given the
limited number of included studies, the variation in design
including dose and duration of omega-3 supplementation, it is
clear that further research is required before recommendations
can be made regarding the optimal dose and duration of therapy
for this patient cohort.
Key Points 
• Omega-3 supplementation decreases liver fat
• The optimal dose required has not been determined, 
supplementation
• Well-designed randomized controlled trials to quantify 
the reductions in liver fat and the optimal dose of 
omega-3 supplementation are urgently required
but benefits are seen with ≥0.83 g/day of omega-3Given that NAFLD is associated with an increased risk of car-
diovascular disease (CVD), potential hepatic beneﬁts of PUFA
therapy should be considered in combination with its effects on
cardio-metabolic risk factors, including insulin resistance and
dyslipidaemia [10,11,13–15]. On the basis of the cohorts included
in the present meta-analyses in which these parameters were
measured: 8 of 9 studies reported a statistically signiﬁcant bene-
ﬁt of omega-3 PUFA supplementation on blood triglycerides
[45,46,48,53–57]; 2 of 5 showed a signiﬁcant improvement in
low-density lipoprotein cholesterol (LDL-c) [46,48] (3 of 5
reported non-signiﬁcant changes [53,56,57]) and 1 of 4 studies
noted an improvement in fasting glucose concentration [45] (3
of 4 reported non-signiﬁcant changes [47,53,56]). The sole study
that measured blood pressure reported signiﬁcant improvements
in systolic and diastolic blood pressure [56]. However, undertak-
ing meta-analyses on this sub-set of data would not be appropri-
ate as it fails to represent the larger body of evidence available
regarding the effect of omega-3 PUFA supplementation on gly-
caemic control, blood pressure, lipids, and lipoproteins. There is
clear evidence from meta-analyses that PUFA supplementation
improves blood triglycerides [58–60] and blood pressure [61]Journal of Hepatology 201but is associated with a small elevation in LDL-c [58–60]. There
is some evidence to suggest that PUFA supplementation may ele-
vate fasting blood glucose concentration [59], but the weight of
data suggests that this is not signiﬁcant [58,60].
It should be noted that the study by Zhu et al. [48] used die-
tary intervention in conjunction with omega-3 PUFA supplemen-
tation whereas Chen et al. [55] did not, and the results may be
inﬂuenced by dietary intake. It is notable that three of the four
available RCTs used a combination of omega-3 supplementation
with dietary recommendations or diet therapy, and the addition
of this dietary component may also have had a marked effect
on serum liver enzymes and liver steatosis. A potential limitation
of our data is that we pooled data from different measurement
techniques for liver fat analysis (MRS, ultrasound). Importantly,
we have reported ES which is based on the mean change and var-
iability between intervention and control groups as opposed to
quantitative changes, which mitigates this problem. Although
pooling data in this way could be confounded by differences in
measurement error of the techniques (the reported coefﬁcient
of variation for MRS is lower than ultrasound [62]) 6 of the 7
studies in the pooled meta-analysis and all (4 of 4) in the RCT-
only meta-analysis used the same measurement technique
(ultrasound). We acknowledge that, at present, there is a lack
of data from more sensitive, readily-available techniques such
as MRS and suggest that this should be a pre-requisite in future
studies.
Individuals with NAFLD have been shown to have a lower die-
tary intake of omega-3 fatty acids than healthy controls [36,63],
and biochemical analyses have shown alteration in the hepatic
long chain fatty acid composition towards an increase in the
n6/n3 ratio. Animal data has shown that this is associated
with a pro-inﬂammatory state [64–66] and increased lipogenesis
leading to steatosis [42,49,67]. Conversely, omega-3 PUFAs are
known to down-regulate sterol regulatory element binding pro-
tein 1c (SREBP-1c) and upregulate peroxisome proliferator acti-
vated receptor a (PPAR-a) which would favour fatty acid
oxidation and reduce steatosis [1]. Given these observations
and the fact that omega-3 PUFAs are essential in the human diet
and unable to be synthesised de novo, dietary supplementation of
n3 PUFAs has been suggested to be efﬁcacious for the manage-
ment of NAFLD [67]. Our data support PUFA supplementation as
effective for liver fat reduction in human trials, as indicated by a
signiﬁcant and strong effect size. This compares favourably with
other pharmaceutical and nutraceutical interventions including
metformin, simvastatin, ursodeoxycholic acid, vitamins E and C,
and betaine [32]. A reduction in steatosis with omega-3 PUFA
supplementation in the absence of weight loss was shown in ﬁve
of the studies reviewed, which is clinically signiﬁcant, and sup-
plementation led to the amelioration of liver steatosis as inferred
by ultrasonography for 27% of patients who received omega-3
supplementation in these studies [45,47,48,53,54]. However,
there is currently little information concerning the magnitude
of hepatic beneﬁt as assessed by magnetic resonance imaging
(MRI), which is considered to be the gold standard for quantifying
liver fat [68,69]. Nine RCTs (clinicaltrials.gov identiﬁer:
NCT00819338, NCT00230113, NCT01277237, NCT01285362,
NCT00760513, NCT00681408, NCT00845845, NCT01154985) are
currently evaluating omega-3 PUFA in NAFLD or NASH and their
results should provide additional information.
The present analysis represents the ﬁrst systematic review
suggesting that omega-3 PUFA supplementation can reduce liver2 vol. 56 j 944–951 949
Review
steatosis in humans. From the available data, there is no evidence
of a signiﬁcant effect on liver tests. The limited number of RCTs,
variable study designs and potential confounding from differen-
tial dietary intake, limit the strength of available data. Additional
well-designed and larger randomised controlled trials are
required to establish optimal doses, deﬁne appropriate patient
groups and to quantify the beneﬁt of omega-3 PUFA therapy in
patients with NAFLD.Conﬂict of interest
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